Citations

Clear

1792 citation(s) found for "Stephanie".

GLI1/GLI2 functional interplay is required to control Hedgehog/GLI targets gene expression
Tolosa, Ezequiel J. , Iguchi, Eriko , McCleary‐Wheeler, Angela L. , Carr, Ryan M. , Almada, Luciana L. , Flores, Luis F. , Vera, Renzo E., Alfonse, Germine W., Marks, David L. , Hogenson, Tara L. , Vrabel, Anne M., Horn, Isaac P. , Koenig, Amanda, Safgren, Stephanie L. , Sigafoos, Ashley N. , Erkan, Mert , Romecín, Paola , Gonzalez, Alejandro Sarabia, Javelaud, Delphine , Marsaud, Véronique, Graham, Rondell P. , Elsawa, Sherine F. , Fernández-Zapico, Martín E. , Fernandez-Barrena, Maite G, McCleary-Wheeler, Angela L, Koenig, Amanda N, Romecin-Duran, Paola A, Sarabia Gonzalez, Alejandro, Elsawa, Sherine F , Graham, Rondell P , Safgren, Stephanie L , Carr, Ryan M , Fernández‐Barrena, Maite G. , Zhou, Bo , Mauviel, Alain

Mayo Clinic

Biochemical Journal | August 7, 2020 | Volume: 477 | Issue: 17 | Pages: 3131-3145

10.1042/bcj20200335 | PMID 32766732 Get It

The Hedgehog-regulated transcription factors GLI1 and GLI2 play overlapping roles in development and disease; however, the mechanisms underlying their interplay remain elusive. We report for the first time that GLI1 and GLI2 physically and functionally interact in cancer cells. GLI1 and GLI2 were shown to co-immunoprecipitate in PANC1 pancreatic cancer cells and RMS13 rhabdomyosarcoma cells. Mapping analysis demonstrated that the zinc finger domains of both proteins are required for their heteromerization. RNAi knockdown of either GLI1 or GLI2 inhibited expression of many well-characterized GLI target genes (BCL2, MYCN, PTCH2, IL7 and CCND1) in PANC1 cells, whereas PTCH1 expression was only inhibited by GLI1 depletion. qPCR screening of a large set of putative canonical and non-canonical Hedgehog/GLI targets identified further genes (e.g. E2F1, BMP1, CDK2) strongly down-regulated by GLI1 and/or GLI2 depletion in PANC1 cells, and demonstrated that ANO1, AQP1 and SOCS1 are up-regulated by knockdown of either GLI1 or GLI2. Chromatin immunoprecipitation showed that GLI1 and GLI2 occupied the same regions at the BCL2, MYCN and CCND1 promoters. Furthermore, depletion of GLI1 inhibited GLI2 occupancy at these promoters, suggesting that GLI1/GLI2 interaction is required for the recruitment of GLI2 to these sites. Together, these findings indicate that GLI1 and GLI2 co-ordinately regulate the transcription of some genes, and provide mechanistic insight into the roles of GLI proteins in carcinogenesis.
Association Between Body Mass Index and Female Sexual Dysfunction: A Cross-sectional Study from the Data Registry on Experiences of Aging, Menopause, and Sexuality
Fairbanks, Flávia, Kuhle, Carol L. , Sood, Richa , Kling, Juliana M. , Vencill, Jennifer A. , Mara, Kristin C. , Kapoor, Ekta , Mara, Kristin C , Kling, Juliana M , Faubion, Stephanie S. , Kapoor, Ekta

Mayo Clinic

The Journal of Sexual Medicine | August 5, 2020 | Volume: 17 | Issue: 10 | Pages: 1971-1980

10.1016/j.jsxm.2020.07.004 | PMID 32771351 Get It

Abstract Background Obesity and female sexual dysfunction (FSD) are prevalent conditions, and both are associated with significant adverse effects on health and well-being. Aim To investigate the association between body mass index and FSD, as well as potential moderators. Methods This cross-sectional study was performed by analyzing medical records of 6,688 women seeking consultation for menopause-related or sexual health–related concerns at women’s health clinics at Mayo Clinic Rochester, MN, and Scottsdale, AZ, between May 1, 2015, and September 15, 2019. Outcomes Female sexual function was assessed by the Female Sexual Function Index, and sexual distress was assessed by the Female Sexual Distress Scale-Revised. Results Being overweight or obese was associated with a lack of sexual activity. Among sexually active women, those who were overweight or obese had lower Female Sexual Function Index total scores and sexual function domain scores (indicating worse sexual function), including sexual arousal, lubrication, satisfaction, orgasm, and pain, and higher levels of sexual distress than those with normal weight. However, on multivariable analysis, these associations were found to be mediated by other factors, including age, level of education, reproductive stage, medication use, and mood disturbances, which are known to impact body weight and sexual function in women. Clinical Implications Overweight and obesity were associated with sexual inactivity and greater odds of having FSD, which should prompt proactive assessment of sexual function. Strengths and Limitations The strengths of this study include the large cohort size and assessment of sexual problems in addition to sexual distress, a key component of the definition of sexual dysfunction. This study also took into account multiple potential moderating factors. Limitations include the cross-sectional design, which precludes determination of causality as well as lack of diversity in the cohort, potentially limiting generalizability of results. In addition, sexual function was not assessed in women reporting no recent sexual activity, which may confound results. Conclusion Overweight/obesity and FSD are highly prevalent conditions, which appear to be indirectly associated. These results highlight the need to identify and address FSD in all overweight and obese women, with particular attention to potential contributing factors.
Hearing loss and microstructural integrity of the brain in a dementia‐free older population
Croll, Pauline H. , Vernooij, Meike W. , Goedegebure, André , Rigters, Stephanie C. , Sharrett, A. Richey , Lin, Frank R. , Reid, Robert I. , Power, Melinda C. , Jong, Robert J. Baatenburg de , Mosley, Thomas H. , Groot, Marius de , Deal, Jennifer A.

Mayo Clinic

Alzheimer's & Dementia | August 2, 2020 | Volume: 16 | Issue: 11 | Pages: 1515-1523

10.1002/alz.12151 | PMID 32743902 Get It

AbstractIntroductionAs hearing loss has been identified as an important risk factor for dementia, we aimed to assess the association between hearing loss and microstructural integrity of the brain.MethodsA total of 1086 dementia‐free participants (mean age = 75.2 [standard deviation: 4.9], 61.4% female) of the population‐based Atherosclerosis Risk in Communities (ARIC) study underwent hearing assessment (2016–2017) and magnetic resonance imaging of the brain (2011–2013). Microstructural integrity was determined with diffusion tensor imaging. Multivariable linear regression was used to investigate associations between hearing loss and microstructural integrity of different brain regions and white matter (WM) tracts.ResultsHearing loss was associated with lower WM microstructural integrity in the temporal lobe, lower gray matter integrity of the hippocampus, and with lower WM microstructural integrity of the limbic tracts and the uncinate fasciculus.ConclusionOur results demonstrate that hearing loss is indepedently associated with lower microstructural integrity in brain regions that are important for different cognitive processes.
A practical guide to feedback in the workplace: Interpreting and acting on feedback from learners and direct reports
Gore, Stephanie , Schlosser, Elizabeth G , Quach, David

Mayo Clinic

American Journal of Health-System Pharmacy | July 30, 2020 | Volume: 77 | Issue: 19 | Pages: 1552-1555

10.1093/ajhp/zxaa155 | PMID 32729611 Get It

The Efficacy of Dynamic Stabilization of the First Carpometacarpal Joint: A Prospective Randomized Controlled Trial
Martino, Kaylee, Murphy, Sara McCurdy, Jesus, Celine De, Ivy, Cindy, Kannas, Stephanie , McVeigh, Kimberly H. , Nickolaou, Allison, Murphy, Sara

Mayo Clinic

American Journal of Occupational Therapy | July 29, 2020 | Volume: 74 | Issue: 1_suppl | Pages: No page available

10.5014/ajot.2020.74s1-po3720 Get It

Date Presented 03/26/20 In adults with first carpometacarpal degenerative joint disease, does a dynamic stabilization home exercise program (HEP) decrease pain and increase function more than a traditional HEP? Research is needed to assess if this approach will lead to greater function and less pain than the currently accepted approach. It is important for OTs to have a holistic approach that includes traditional joint protection, orthosis use, and self-management of HEPs. Primary Author and Speaker: Cindy Ivy Additional Authors and Speakers: Kaylee Martino, Sara Murphy, Celine De Jesus, Stephanie Kannas, Kimberly McVeigh, Allison Nickolaou
A selective serotonin receptor agonist for weight loss and management of menopausal vasomotor symptoms in overweight midlife women: a pilot study
Kapoor, Ekta , Schroeder, Darrell R. , Fokken, Shawn C. , Croghan, Ivana T. , Faubion, Stephanie, Hurt, Ryan T. , Fischer, Karen, Schroeder, Darrell, Fokken, Shawn, Schroeder, Darrell , Faubion, Stephanie S. , Fischer, Karen M.

Mayo Clinic

Menopause | July 29, 2020 | Volume: 27 | Issue: 11 | Pages: 1228-1235

10.1097/gme.0000000000001599 | PMID 33110038 Get It

Abstract Objective: Weight gain and vasomotor symptoms (VMS) are common complaints in midlife women going through the menopause transition. A selective serotonin 2C (5-HT2C) receptor agonist, lorcaserin, which was previously approved by the Food and Drug Administration for weight loss, has unreported observational evidence suggesting improvement in VMS with its use. The goal of this pilot study was to evaluate the efficacy of lorcaserin for weight loss and management of VMS in overweight midlife women. Methods: This was a 24-week open label pilot study of 20 overweight midlife women, aged 45-60 years, who were experiencing severe VMS. Participants received lorcaserin at the standard dose of 10 mg twice daily for 12 weeks, followed by 12 weeks of observation off the drug. The primary outcomes were changes in weight and subjectively reported VMS. Results: At the end of 12 weeks, mean change in weight was −2.4 kg (90% CI, −3.2 to −1.7, P < 0.001). However, the participants returned to the baseline weight at 24 weeks. Participants also reported significant subjective improvement in VMS, with a mean ± SD change in self-reported hot flash frequency from baseline to week 12 of −5.4 ± 3.9 (decrease of 1.4 standard deviations). There was a rapid increase in the frequency of VMS within 2 weeks of discontinuation of lorcaserin with a tendency to approach the baseline frequency of VMS. Conclusions: In addition to its weight loss-inducing effect, 5-HT2C receptor modulation may have an additional beneficial effect on VMS in midlife women. A treatment option that targets both weight and VMS in midlife women is attractive. Video Summary: http://links.lww.com/MENO/A622.
Current trends in health coaching for chronic conditions
Yang, Juan , Bauer, Brent A. , Lindeen, Stephanie A. , Dabrh, Abd Moain Abu , Boehmer, Kasey R. , Salinas, Manisha , Cutshall, Susanne M. , Abu Dabrh, Abd Moain, Abu Dabrh, Abd Moain , Perlman, Adam

Mayo Clinic

Medicine | July 21, 2020 | Volume: 99 | Issue: 30 | Pages: e21080

10.1097/md.0000000000021080 | PMID 32791680 Get It

Abstract Background: Chronic conditions are placing a serious burden on individuals as well as the health care system. Health coaching (HC) has emerged as a promising approach that can support effective lifestyle interventions for chronic conditions. However, until now there is no particularly comprehensive systematic review of HC impact on a chronic condition from the angle of patient improvement and detail coaching characteristics reported. Objective: To synthesize available studies on the efficacy and current status of HC interventions on the health of chronically ill adult patients. Methods: The literature search will be conducted for trials published in English within the past four years. Electronic databases CINAHL, Cochrane Library, Embase, MEDLINE, and Scopus will be searched with keywords describing HC for chronic diseases. Randomized controlled trials that compare HC interventions to conventional care or other alternative therapies will be included. Data extraction will be conducted by two reviewers independently, and enrolled trials will be evaluated for quality and bias assessment. If appropriate, meta-analysis will be conducted on the last stage of the review; otherwise, the study findings will be described narratively. The software Review Manager (Revman version 5.3.5.) provided by the Cochrane Collaboration will be applied for the meta-analysis. Results: This is the first study to comprehensively explore the effectiveness and current status of HC intervention for patients with chronic conditions. Discussion: Study findings from this review will advance the appropriate utilization of coaching practice by determining whether HC is effective and feasible among patients with chronic disease. If proven effective, this approach may be applied more broadly through public health interventions. The current status findings will also provide evidence to inform decisions for integrating HC interventions into the current management pathway for individuals with chronic conditions. Systematic review registration: PROSPERO CRD42020153280.
Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical description, biomarker status, biochemical analysis, and treatmen
Ng, Bobby G. , Eklund, Erik A. , Shiryaev, Sergey A., Dong, Yin Yao , Abbott, Mary‐Alice , Asteggiano, Carla , Bamshad, Michael J. , Barr, Eileen , Bernstein, Jonathan A. , Chelakkadan, Shabeed, Ciliberto, Michael A. , Cousin, Janice, Gardiner, Fiona, Ghosh, Suman , Graf, W. , Grünewald, Stephanie , Hammond, Katherine, Hauser, Natalie , Hoganson, George, Houck, Kimberly , Kohler, Jennefer N., Liu, Pengfei , Madathil, Sujana , McCormack, Colleen E., Meeks, Naomi, Miller, Rebecca L. , Monaghan, Kristin G. , Nickerson, Deborah A. , Palculict, Timothy Blake, Papazoglu, Gabriela M., Pletcher, Beth A. , Scheffer, Ingrid E. , Schenone, Andrea, Schnur, Rhonda E. , Si, Yue , Rowe, Leah J., Russi, Alvaro H. Serrano, Russo, Rossana Sanchez , Thabet, Farouq , Tuite, Allysa , Villanueva, Marıá Mercedes, Webster, Richard , Wilson, Dorcas, Zalan, Alice, Wolfe, Lynne A. , Rhodes, Lindsay, Scheffer, Ingrid E , Ng, Bobby G , Christodoulou, John , Chung, Wendy K. , Morava, Éva , Larson, Austin , Miller, Rebecca, Monaghan, Kristin G. , Rowe, Leah J., Wang, Raymond , Rosenfeld, Jill A. , Freeze, Hudson H.

Mayo Clinic

Journal of Inherited Metabolic Disease | July 18, 2020 | Volume: 43 | Issue: 6 | Pages: 1333-1348

10.1002/jimd.12290 | PMID 32681751 Get It

Abstract Asparagine‐linked glycosylation 13 homolog ( ALG13 ) encodes a nonredundant, highly conserved, X‐linked uridine diphosphate (UDP)‐ N ‐acetylglucosaminyltransferase required for the synthesis of lipid linked oligosaccharide precursor and proper N‐linked glycosylation. De novo variants in ALG13 underlie a form of early infantile epileptic encephalopathy known as EIEE36, but given its essential role in glycosylation, it is also considered a congenital disorder of glycosylation (CDG), ALG13‐CDG. Twenty‐four previously reported ALG13‐CDG cases had de novo variants, but surprisingly, unlike most forms of CDG, ALG13‐CDG did not show the anticipated glycosylation defects, typically detected by altered transferrin glycosylation. Structural homology modeling of two recurrent de novo variants, p.A81T and p.N107S, suggests both are likely to impact the function of ALG13. Using a corresponding ALG13‐deficient yeast strain, we show that expressing yeast ALG13 with either of the highly conserved hotspot variants rescues the observed growth defect, but not its glycosylation abnormality. We present molecular and clinical data on 29 previously unreported individuals with de novo variants in ALG13 . This more than doubles the number of known cases. A key finding is that a vast majority of the individuals presents with West syndrome, a feature shared with other CDG types. Among these, the initial epileptic spasms best responded to adrenocorticotropic hormone or prednisolone, while clobazam and felbamate showed promise for continued epilepsy treatment. A ketogenic diet seems to play an important role in the treatment of these individuals.
International consensus guidelines for phosphoglucomutase 1 deficiency ( PGM1‐CDG ): Diagnosis, follow‐up, and management
Altassan, Ruqaiah , Radenkovic, Silvia , Edmondson, Andrew C. , Barone, Rita , Brasil, Sandra , Čechová, Anna , Coman, David , Donoghue, Sarah , Falkenstein, Kristina , Ferreira, Vanessa dos Reis , Fiumara, Agata , Francisco, Rita , Grünewald, Stephanie , Jaeken, Jaak , Krasnewich, Donna M., Lam, Christina , Lefeber, Dirk J. , Marques‐da‐Silva, Dorinda , Pascoal, Carlota , Quelhas, Dulce , Raymond, Kimiyo , Rymen, Daisy , Seroczyńska, Małgorzata, Serrano, Mercedes , Thiel, Christian , Tort, Frederic , Vals, Mari‐Anne , Videira, Paula A. , Raymond, Kimiyo M, Donoghue, Sarah E , Edmondson, Andrew C , Pascoal, Carlota , Videira, Paula A , Ferreira, Carlos R , Freeze, Hudson H. , Honzík, Tomáš , Lee, Joy Li-Yueh , Sykut‐Cegielska, Jolanta , Voermans, Nicol Cornelia , Witters, Peter , Morava, Éva

Mayo Clinic

Journal of Inherited Metabolic Disease | July 18, 2020 | Volume: 44 | Issue: 1 | Pages: 148-163

10.1002/jimd.12286 | PMID 32681750 Get It

Abstract Phosphoglucomutase 1 (PGM1) deficiency is a rare genetic disorder that affects glycogen metabolism, glycolysis, and protein glycosylation. Previously known as GSD XIV, it was recently reclassified as a congenital disorder of glycosylation, PGM1‐CDG. PGM1‐CDG usually manifests as a multisystem disease. Most patients present as infants with cleft palate, liver function abnormalities and hypoglycemia, but some patients present in adulthood with isolated muscle involvement. Some patients develop life‐threatening cardiomyopathy. Unlike most other CDG, PGM1‐CDG has an effective treatment option, d ‐galactose, which has been shown to improve many of the patients' symptoms. Therefore, early diagnosis and initiation of treatment for PGM1‐CDG patients are crucial decisions. In this article, our group of international experts suggests diagnostic, follow‐up, and management guidelines for PGM1‐CDG. These guidelines are based on the best available evidence‐based data and experts' opinions aiming to provide a practical resource for health care providers to facilitate successful diagnosis and optimal management of PGM1‐CDG patients.
A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers
Powers, Jacquelyn , Pinto, Emília M. , Barnoud, Thibaut , Leung, Jessica C. , Martynyuk, Tetyana , Kossenkov, Andrew V. , Philips, Aaron H., Desai, Heena , Hausler, Ryan , Le, Anh N. , Pyle, Louise C. , Zelley, Kristin , Nathanson, Katherine L. , Slavin, Thomas P. , Weitzel, Jeffrey N. , Stopfer, Jill E. , Offit, Kenneth , Dolinsky, Jill S. , Gutierrez, Stephanie, McGoldrick, Kelly , Levin, Brooke , Edelman, Morris, Levy, Carolyn Fein , Spunt, Sheri L. , Zambetti, Gerard P. , Li, Marilyn M , MacFarland, Suzanne P , Pyle, Louise C , Zelley, Kristin , Domchek, Susan M , Weitzel, Jeffrey N , Garber, J. E. , Joseph, Vijai , Levin, Brooke , Levy, Carolyn Fein , Spunt, Sheri L , Nathanson, Katherine L , Kelly, Gregory, Domchek, Susan M. , Garber, Judy E. , Vijai, Joseph , Couch, Fergus J. , Kriwacki, Richard W. , Ribeiro, Raul C , Murphy, Maureen E. , Maxwell, Kara N.

Mayo Clinic

Cancer Research | July 16, 2020 | Volume: 80 | Issue: 17 | Pages: 3732-3744

10.1158/0008-5472.can-20-1390 | PMID 32675277 Get It

Abstract Germline mutations in TP53 cause a rare high penetrance cancer syndrome, Li–Fraumeni syndrome (LFS). Here, we identified a rare TP53 tetramerization domain missense mutation, c.1000G&gt;C;p.G334R, in a family with multiple late-onset LFS-spectrum cancers. Twenty additional c.1000G&gt;C probands and one c.1000G&gt;A proband were identified, and available tumors showed biallelic somatic inactivation of TP53. The majority of families were of Ashkenazi Jewish descent, and the TP53 c.1000G&gt;C allele was found on a commonly inherited chromosome 17p13.1 haplotype. Transient transfection of the p.G334R allele conferred a mild defect in colony suppression assays. Lymphoblastoid cell lines from the index family in comparison with TP53 normal lines showed that although classical p53 target gene activation was maintained, a subset of p53 target genes (including PCLO, PLTP, PLXNB3, and LCN15) showed defective transactivation when treated with Nutlin-3a. Structural analysis demonstrated thermal instability of the G334R-mutant tetramer, and the G334R-mutant protein showed increased preponderance of mutant conformation. Clinical case review in comparison with classic LFS cohorts demonstrated similar rates of pediatric adrenocortical tumors and other LFS component cancers, but the latter at significantly later ages of onset. Our data show that TP53 c.1000G&gt;C;p.G334R is found predominantly in Ashkenazi Jewish individuals, causes a mild defect in p53 function, and leads to low penetrance LFS. Significance: TP53 c.1000C&gt;G;p.G334R is a pathogenic, Ashkenazi Jewish–predominant mutation associated with a familial multiple cancer syndrome in which carriers should undergo screening and preventive measures to reduce cancer risk.